A biomarker-guided strategy that combines tumor visibility, immune-cell state, spatial architecture, systemic inflammation, and early treatment dynamics to identify the dominant resistance topology is proposed to restore productive immune pressure while limiting compensatory escape and toxicity.
Abstract
PD-1/PD-L1 blockade can produce durable tumor control, yet primary, adaptive, and acquired resistance remain common. Existing accounts often catalogue resistance by cellular compartment, obscuring the coordinated nature of tumor adaptation. Here, we introduce immune-pressure redistribution as a treatment-oriented framework that complements cancer immunoediting by asking where therapeutic immune pressure is diverted after checkpoint release. Resistance is organized into three coupled routes: transfer into tumor-intrinsic escape through antigen-presentation loss, interferon-response defects, oncogenic rewiring, and lineage plasticity; weakening through defective priming, terminal T-cell differentiation, compensatory checkpoints, metabolic constraint, and chronic cytokine signaling; and unloading into stromal, vascular, myeloid, regulatory, microbial, and systemic host compartments. We integrate clinically validated mechanisms with emerging evidence, including the temporal duality of interferon–JAK signaling, the role of tumor-draining lymph nodes in sustaining progenitor-exhausted T cells, and the limited translation of TIGIT, IDO1, TGF-β, and CSF-1R targeting. We further propose a biomarker-guided strategy that combines tumor visibility, immune-cell state, spatial architecture, systemic inflammation, and early treatment dynamics to identify the dominant resistance topology. This framework supports topology-matched combinations and adaptive sequencing rather than uniform escalation, with the aim of restoring productive immune pressure while limiting compensatory escape and toxicity.
Programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) immune checkpoint inhibitors have redefined the therapeutic landscape of advanced melanoma, establishing a first-line standard of care that markedly prolongs patient survival. Nevertheless, primary and acquired resistance remain the principal barr...
Yu-Hua Li, Jing Wu, Wei-Ming Liao et al.· Frontiers in Pharmacology· 0 citations
This review synthesizes the current landscape of PD-1/PD-L1-directed ICIs, dissect the molecular and cellular determinants of intrinsic and acquired resistance, and discusses emerging pharmacological strategies to overcome them, including next-generation checkpoint combinations.
A. Kim, Nawon Lee, Hung-Yu Chen et al.· Pharmacological Research· 0 citations
This review integrates the major tumor-intrinsic and tumor-extrinsic mechanisms that drive ICI resistance, including defective antigen presentation, impaired interferon signaling, oncogenic and epigenetic immune escape programs, metabolic rewiring, suppressive myeloid and stromal circuits, abnormal vasculature, and pro...
R. Karataş, Yaren Alras, Sarenur Teki̇ner et al.· Immunologic research· 0 citations
It is proposed that rational combinations of STING agonists with Fc-engineered PD-L1/PD-L2-targeting antibodies, guided by dynamic and spatial biomarkers, could overcome resistance to conventional immune checkpoint blockade in tumors with minimal T-cell infiltration but targetable tumor vasculature.
Akash R. Boda, E. Bolli, A. Salameh et al.· Frontiers in Immunology· 0 citations
The central conclusion of this review is that effective clinical translation will necessitate a paradigm shift from discrete pathway inhibition toward integrated precision immuno-oncology strategies that combine molecular profiling, immune-contexture analysis, and mechanism-based combination therapies.
Yu-Yu Xu, Huiling Shen· Iranian journal of immunolog...· 0 citations
Immune checkpoint blockade (ICB) produces durable tumor control in a subset of patients, yet resistance is usually interpreted through tumor-intrinsic lesions or suppression within the tumor microenvironment (TME). We propose that ICB resistance can also be organized as failure of a multiscale antitumor immune circuit...
Xue Zhao, Han Wang, Ya-Nan Liu et al.· Frontiers in Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.